Innate Pharma S.A. (NASDAQ:IPHA) has earned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.
Brokerages have set a 1-year consensus price objective of $11.50 for the company, according to Zacks. Zacks has also assigned Innate Pharma an industry rank of 94 out of 255 based on the ratings given to related companies.
A number of research firms have issued reports on IPHA. Svb Leerink reissued an “outperform” rating on shares of Innate Pharma in a research report on Monday, November 11th. HC Wainwright reaffirmed a “buy” rating on shares of Innate Pharma in a research report on Tuesday, November 26th. Finally, Zacks Investment Research downgraded Innate Pharma from a “hold” rating to a “sell” rating in a research report on Tuesday, January 14th.
Shares of NASDAQ:IPHA traded up $0.34 during midday trading on Friday, reaching $7.61. The company’s stock had a trading volume of 15,658 shares. The company’s 50 day moving average is $6.54. Innate Pharma has a 1 year low of $5.61 and a 1 year high of $8.24.
About Innate Pharma
Innate Pharma SA, a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. The company offers IPH4102, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for cutaneous T-cell lymphomas; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat various cancer indications and tumors; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils.
Featured Story: Holder of Record
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.